European Results From Global ETNA-AF Registry Show Low Bleeding and Low Cardiovascular Event Rates in Elderly NVAF Patients on LIXIANA®▼ (edoxaban)

Read MORE

MUNICH, Oct. 12, 2019 /PRNewswire/ — Daiichi Sankyo Europe GmbH (hereafter, “Daiichi Sankyo”) today announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients, mostly elderly, treated with edoxaban (known by the brand name…

Share:

Author: HEDGE

Executive Editor and Founder of HEDGEaccordingly.com. Hedge Was Founded in January 22, 2008. Learn more about HEDGEaccordingly